Penn study shows both sides of the cells of the immune system could be used to shrink tumors

Recently identified a cell that leads to other immune cells to fight infection plays a crucial role in regulating the immune system in health and disease. Researchers at the University of Pennsylvania School of Medicine have discovered how a molecule stimulates a protein on the membrane of another cell of the immune system T helper 17 cells are multi-tasking of all kinds. Th17 cells protect the body against infection, but they are also guilty of some autoimmune diseases and out of control, the growth of cancer cells.These fundamental discoveries of Th17 cells in peripheral blood cells of the bone and has vast implications, providing the basis for a new protocol for the treatment of human cancer. T-cell therapies that integrate the signal ICOS Penn are expected to treat patients.

Tip the balance between stimulating and suppressing the growth of Th17 cells may be the key to immunotherapy couture, a form of cancer treatment. The adoptive transfer of tumor-specific cells expanded with ICOS and polarized to a type of Th17 cells may improve treatment.

The solution is very sophisticated ‘smart choice’ of the sites of interaction of antibodies specific hormones that may differ from similar sites of other hormones from a single molecule.

This knowledge to get closer to the clinic, the team also found that Th17 cells can only be extended to many, but it could also be maintained, with stimulating protein ICOS. Polarizing Th17 cytokines have been shown to support the cells had CD4 Th17 cells, but it is the first demonstration that ICOS co-stimulatory molecules used to expand Th17 cells is important.

Penn’s other co-authors are Carmine Carpenito, Gabriela Plesa, Megan M. Suhoski, Angel Varela-Rohen, Tatiana Golovin, N. Carroll and James L. Riley.

This new understanding that Th17 cells are able to play on both sides of the barrier suggests that the targeting or inhibiting protein pathways involved could be a new way to treat cancer, chronic infections and some autoimmune diseases. Previous studies have linked excessive Th17 cells in the body in autoimmune diseases, such as,,, e.

A patent for the expansion of Th17 cells with ICOS has been made on the basis of the work reported in the published article.